AbsEn.i
Curation
Istex
Racine
Curation
Checkpoint
Istex
Racine
Istex
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Curation (Istex)

Index « AbsEn.i » - entrée « reactive »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
reactivation < reactive < reader  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 38.
[0-20] [0 - 20][0 - 38][20-37][20-40]
Ident.Authors (with country if any)Title
000025 (2014) Shuji Ohta [Japon] ; Tomomi Tsuru [Japon] ; Kimio Terao [Japon] ; Seiji Mogi [Japon] ; Midori Suzaki [Japon] ; Eisuke Shono [Japon] ; Yoshimasa Ishida [Japon] ; Eriko Tarumi [Japon] ; Masato Imai [Japon]Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)
000048 (2012) Hiroki Wakabayashi [Japon] ; Masahiro Hasegawa [Japon] ; Yosuke Nishioka [Japon] ; Yukari Minami [Japon] ; Kusuki Nishioka [Japon] ; Akihiro Sudo [Japon]Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure
000059 (2012) Kevin Kwan [Australie] ; Sneha Bharadwaj [Australie] ; Charles Inderjeeth [Australie]Response to treatment with tocilizumab of reactive arthritis induced by intravesical bacillus Galmette‐Guérin unresponsive to DMARDs
000076 (2011) Makoto Hirao [Japon] ; Naomi Yamasaki [Japon] ; Hiroki Oze [Japon] ; Kosuke Ebina [Japon] ; Akihide Nampei [Japon] ; Yoshitaka Kawato [Japon] ; Kenrin Shi [Japon] ; Hideki Yoshikawa [Japon] ; Norihiro Nishimoto [Japon] ; Jun Hashimoto [Japon]Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab
000096 (2009) Hiroe Sato [Japon] ; Takehito Sakai [Japon] ; Toshiaki Sugaya [Japon] ; Yasuhiro Otaki [Japon] ; Kana Aoki [Japon] ; Katsushi Ishii [Japon] ; Hidehiro Horizono [Japon] ; Hiroshi Otani [Japon] ; Asami Abe [Japon] ; Noboru Yamada [Japon] ; Hajime Ishikawa [Japon] ; Kiyoshi Nakazono [Japon] ; Akira Murasawa [Japon] ; Fumitake Gejyo [Japon]Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis
000133 (2009) Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami [Japon] ; Satoshi Yamasaki [Japon] ; Takahiro Imazato [Japon] ; Naoki Iwamoto [Japon] ; Keita Fujikawa [Japon] ; Toshiyuki Aramaki [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Hiroaki Ida [Japon] ; Tomoki Origuchi [Japon] ; Yukitaka Ueki [Japon] ; Katsumi Eguchi [Japon]Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
000146 (2010) G. Horneff [Allemagne]Juvenile Arthritiden
000169 (2015) Yanli Zhuang [États-Unis] ; Dick E. De Vries [Pays-Bas] ; Zhenhua Xu [États-Unis] ; Stanley J. Marciniak Jr. [États-Unis] ; Dion Chen [États-Unis] ; Francisco Leon [États-Unis] ; Hugh M. Davis [États-Unis] ; Honghui Zhou [États-Unis]Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach
000240 (2013) Naoshi Nishina [Japon] ; Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Masataka Kuwana [Japon] ; Tsutomu Takeuchi [Japon]Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression
000314 (2010) Ukihide Tateishi [Japon] ; Tomoyuki Imagawa [Japon] ; Noriko Kanezawa [Japon] ; Tetsuhiko Okabe [Japon] ; Kazuya Shizukuishi [Japon] ; Tomio Inoue [Japon] ; Shumpei Yokota [Japon]PET assessment of disease activity in children with juvenile idiopathic arthritis
000323 (2013) P. I. Novikov [Russie] ; I. O. Smitienko [Russie] ; S. V. Moiseev [Russie]Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature
000507 (2013) Todd A. Morrison [États-Unis] ; Mark Figgie [États-Unis] ; Andy O. Miller [États-Unis] ; Susan M. Goodman [États-Unis]Periprosthetic Joint Infection in Patients with Inflammatory Joint Disease: a Review of Risk Factors and Current Approaches to Diagnosis and Management
000572 (2013) Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; T. Shioura ; N. Asai ; T. Kobayakawa ; K. Saito [Japon] ; N. IshiguroAB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry
000697 (2010) M. Rihl [Allemagne] ; J. G. Kuipers [Allemagne]Reaktive Arthritis
000713 (2011) M. Korppi [Finlande] ; Me Van Gijn [Pays-Bas] ; K. Antila [Finlande]Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report
000737 (2013) A. Ogata [Japon]FRI0218 Normalization of c-reactive protein within the first 8 weeks is a predictive factor for the effectiveness of subcutaneous tocilizumab monotherapy in japanese rheumatoid arthritis patients: results from the musashi study
000830 (2016) Gabriela Cobo [Suède] ; Abdul Rashid Qureshi [Suède] ; Bengt Lindholm [Suède] ; Peter Stenvinkel [Suède]C‐reactive Protein: Repeated Measurements will Improve Dialysis Patient Care
000852 (2013) T. Kojima ; K. Funahashi ; N. Takahashi ; D. Kato ; H. Matsubara ; Y. Hattori ; Y. Yabe [Japon] ; N. IshiguroTHU0124 Importance of monitoring of C-reactive protein level to predict achievement of better clinical outcome during treatment with tocilizumab in patients with rheumatoid arthritis
000861 (2013) Takaaki Ogoshi [Japon] ; Takashi Kido [Japon] ; Kazuhiro Yatera [Japon] ; Keishi Oda [Japon] ; Toshinori Kawanami [Japon] ; Hiroshi Ishimoto [Japon] ; Noriho Sakamoto [Japon] ; Arisa Sano [Japon] ; Chiharu Yoshii [Japon] ; Shohei Shimajiri [Japon] ; Hiroshi Mukae [Japon]Assessment of Pathologically Diagnosed Patients with Castleman’s Disease associated with Diffuse Parenchymal Lung Involvement Using the Diagnostic Criteria for IgG4-Related Disease
000A37 (2008) Takeshi Kuroda [Japon] ; Yasuhiro Otaki [Japon] ; Hiroe Sato [Japon] ; Takeo Fujimura [Japon] ; Takeshi Nakatsue [Japon] ; Syuichi Murakami [Japon] ; Minoru Sakatsume [Japon] ; Masaaki Nakano [Japon] ; Fumitake Gejyo [Japon]A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab
000A57 (2011) Mara Anaís Llamas-Covarrubias [Mexique] ; Yeminia Valle [Mexique] ; Rosa Elena Navarro-Hernández [Mexique] ; Iris Paola Guzmán-Guzmán [Mexique] ; María Guadalupe Ramírez-Due As [Mexique] ; Héctor Rangel-Villalobos [Mexique] ; Ciro Estrada-Chávez [Mexique] ; José Francisco Mu Oz-Valle [Mexique]Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "reactive" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "reactive" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    reactive
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021